At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More
Angel Broking has come out with its earning estimates on pharma sector for the quarter ended September 2011. According to the research firm, Ranbaxy September quarter net sales are expected to go up by 9.1% at Rs 2,054 crore, year-on-year, (YoY) basis.
Pharmaceutical sector has been in the pink of health this year with most stocks outperforming the broader market since the beginning of April. However, there could be some suffering ahead.
KRChoksey has come out with its earning estimates on pharma sector for the quarter ended June 2011. According to the research firm, Ranbaxy June quarter sales are expected to go down by 8% at Rs 1980 crore, year-on-year, (YoY) basis.
Ranbaxy Laboratories is to announce its first quarter CY11 results. According to CNBC-TV18's estimates, it revenues are seen down 23% to Rs 2126 crore versus Rs 2767 crore, year-on-year, YoY, basis.
Motilal Oswal has come out with its earning estimates on Pharmaceuticals sector for the quarter ended March 2011. According to the research firm, Ranbaxy Labs March quarter sales are expected to go up by 13% at Rs 1842 crore, year-on-year, (YoY) basis.
KRChoksey has come out with its earning estimates on pharma sector for the quarter ended March 2011. According to the research firm, Ranbaxy Laboratories March quarter sales are expected to go down by 17% at Rs 2,310 crore, year-on-year, (YoY) basis.
Pharma major Ranbaxy Labs is set to announce its results for the quarter ended December 2010. According to CNBC-TV18 estimates, its profit after tax (PAT) is expected to go up by 23% to Rs 323 crore in Q4CY10 as against Rs 262 crore in same quarter the previous year.
Angel Broking has come out with its earning estimates on the pharmaceutical sector for the quarter ended December 2010. According to the research firm, Ranbaxy Lab December quarter net sales are expected to go up by 0.9% to Rs 2,266 crore, Year-on-Year, (Y-o-Y) basis.
Karvy Stock Broking has come out with its earning estimates on pharma sector for the quarter ended December 2010. According to the research firm, Ranbaxy Laboratories December quarter sales are expected to go down by 2.5% at Rs 2197.7 crore, Year-on-Year, (YoY) basis.
Emkay Global Financial Services has come out with its earning estimates on pharma sector for the quarter ended December 2010. According to the research firm, Ranbaxy December quarter sales are expected to go up by 4.7% to Rs 2361.3 crore, Year-on-Year, (Y-o-Y) basis.
KRChoksey has come out with its earning estimates on pharma sector for the quarter ended December 2010. According to the research firm, Ranbaxy Laboratories December quarter sales are expected to go up by 14% to Rs 2141 crore, Year-on-Year, (Y-o-Y) basis.